Please Wait.....
Report
Generic Drugs Market By Therapeutic Application (Cardiovascular, Infectious Diseases, Cancer, Diabetes, Others), By Route of Administration (Oral, Injections, Others), By Distribution Channel (Hospital pharmacies, Retail pharmacies, Online providers): Global Opportunity Analysis and Industry Forecast, 2023-2032
Market Report I 2023-06-01 I 252 Pages I Allied Market Research
The Generic Drugs Market was valued for $385,320.00 million in 2022 and is estimated to reach $835,706.50 million by 2032, exhibiting a CAGR of 8.1% from 2023 to 2032.
Generic drugs is a medication similar to a branded drug, which has previously been approved for marketing in terms of dose form, potency, mode of administration, quality, performance characteristics, and intended purpose. The generic drugs are available at lower prices as compared to branded drugs.
The growth of the generic drugs market is driven by surge in prevalence of chronic diseases such as diabetes, cancer, and cardiovascular diseases. According to World Cancer Research Fund International (WCRF), there were an estimated 18.1 million cancer cases globally in 2020, of which 9.3 million cases were in men and 8.8 million in women. In addition, the affordable price of generic drugs and latest product approval and product launch contribute to the growth of the market. For instance, in February 2021, Glenmark Pharmaceuticals, a research-led, global integrated pharmaceutical company, announced the launch of SUTIB, the generic version of Sunitinib oral capsules to treat kidney cancer in India.
Moreover, the rise in cost of branded medication, high demand for generic medicines, and rise in awareness about generic drugs contribute to the growth of the market. In addition, prominent players in the global generic drugs market have adopted various strategies such as product launches, acquisition, and investments in R&D for advancement in generic drugs to strengthen their position in the market and sustain the competitive environment.
Moreover, alarming increase in prevalence of diabetes, technological advancements in generic drugs, and rise in the geriatric population are some of the key factors driving the growth of the market. The geriatric population are more prone to chronic diseases such as diabetes and hypertension. However, concern related to the consistency and stability of generic drugs hamper the market growth. Conversely, increase in awareness of generic drugs among the population is expected to provide lucrative opportunities for the growth of the market in the near future. In addition, extensive R&D activities in the field of generic drugs along with significant improvement in medical infrastructure is anticipated to open new avenues for the expansion of the market during the forecast period.
The generic drugs market is segmented into therapeutic application, route of administration, distribution channel, and region. On the basis of therapeutic application, the market is divided into cardiovascular, infectious diseases, cancer, diabetes, and others. Based on the route of administration, the market is classified into oral, injection and others.
Depending on distribution channel, it is classified into hospital pharmacies, retail pharmacies, and online providers. Region-wise, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, UK, Italy, Spain, and rest of Europe), Asia-Pacific (Japan, China, Australia, India, South Korea, and rest of Asia-Pacific), and LAMEA (Brazil, South Africa, Saudi Arabia, and rest of LAMEA).
Major companies profiled in the report include Amneal Pharmaceuticals, Aurobindo Pharma, Cipla, GlaxoSmithKline Plc, Hikma Pharmaceuticals, Lupin Pharmaceuticals, Sandoz International GmbH, Sun Pharmaceuticals, Teva Pharmaceutical Industries Ltd., and Viatris Inc.
Key Benefits For Stakeholders
-This report provides a quantitative analysis of the market segments, current trends, estimations, and dynamics of the generic drugs market analysis from 2022 to 2032 to identify the prevailing generic drugs market opportunities.
-The market research is offered along with information related to key drivers, restraints, and opportunities.
-Porter's five forces analysis highlights the potency of buyers and suppliers to enable stakeholders make profit-oriented business decisions and strengthen their supplier-buyer network.
-In-depth analysis of the generic drugs market segmentation assists to determine the prevailing market opportunities.
-Major countries in each region are mapped according to their revenue contribution to the global market.
-Market player positioning facilitates benchmarking and provides a clear understanding of the present position of the market players.
-The report includes the analysis of the regional as well as global generic drugs market trends, key players, market segments, application areas, and market growth strategies.
Key Market Segments
By Distribution Channel
- Hospital pharmacies
- Retail pharmacies
- Online providers
By Therapeutic Application
- Cardiovascular
- Infectious Diseases
- Cancer
- Diabetes
- Others
By Route of Administration
- Oral
- Injections
- Others
By Region
- North America
- U.S.
- Canada
- Mexico
- Europe
- Germany
- France
- UK
- Italy
- Spain
- Rest of Europe
- Asia-Pacific
- China
- Japan
- India
- Australia
- South Korea
- Rest of Asia-Pacific
- LAMEA
- Brazil
- Saudi Arabia
- South Africa
- Rest of LAMEA
- Key Market Players
- Amneal Pharmaceuticals, Inc.
- Aurobindo Pharma
- Cipla Ltd
- GlaxoSmithKline plc
- Hikma Pharmaceuticals PLC
- Lupin
- Novartis AG
- Sun Pharmaceutical Industries Ltd
- Teva Pharmaceutical Industries Limited
- Viatris Inc.
CHAPTER 1: INTRODUCTION
1.1. Report description
1.2. Key market segments
1.3. Key benefits to the stakeholders
1.4. Research Methodology
1.4.1. Primary research
1.4.2. Secondary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. CXO Perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top impacting factors
3.2.2. Top investment pockets
3.3. Porter's five forces analysis
3.3.1. Moderate bargaining power of suppliers
3.3.2. Moderate threat of new entrants
3.3.3. Moderate threat of substitutes
3.3.4. Moderate intensity of rivalry
3.3.5. Moderate bargaining power of buyers
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of chronic diseases
3.4.1.2. Availability of low-cost generic drugs
3.4.1.3. Upsurge in geriatric population
3.4.2. Restraints
3.4.2.1. Concern related to the quality of generic drugs
3.4.3. Opportunities
3.4.3.1. Patent expiry of branded drugs and new product approvals
3.5. COVID-19 Impact Analysis on the market
CHAPTER 4: GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION
4.1. Overview
4.1.1. Market size and forecast
4.2. Cardiovascular
4.2.1. Key market trends, growth factors and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market share analysis by country
4.3. Infectious Diseases
4.3.1. Key market trends, growth factors and opportunities
4.3.2. Market size and forecast, by region
4.3.3. Market share analysis by country
4.4. Cancer
4.4.1. Key market trends, growth factors and opportunities
4.4.2. Market size and forecast, by region
4.4.3. Market share analysis by country
4.5. Diabetes
4.5.1. Key market trends, growth factors and opportunities
4.5.2. Market size and forecast, by region
4.5.3. Market share analysis by country
4.6. Others
4.6.1. Key market trends, growth factors and opportunities
4.6.2. Market size and forecast, by region
4.6.3. Market share analysis by country
CHAPTER 5: GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION
5.1. Overview
5.1.1. Market size and forecast
5.2. Oral
5.2.1. Key market trends, growth factors and opportunities
5.2.2. Market size and forecast, by region
5.2.3. Market share analysis by country
5.3. Injections
5.3.1. Key market trends, growth factors and opportunities
5.3.2. Market size and forecast, by region
5.3.3. Market share analysis by country
5.4. Others
5.4.1. Key market trends, growth factors and opportunities
5.4.2. Market size and forecast, by region
5.4.3. Market share analysis by country
CHAPTER 6: GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospital pharmacies
6.2.1. Key market trends, growth factors and opportunities
6.2.2. Market size and forecast, by region
6.2.3. Market share analysis by country
6.3. Retail pharmacies
6.3.1. Key market trends, growth factors and opportunities
6.3.2. Market size and forecast, by region
6.3.3. Market share analysis by country
6.4. Online providers
6.4.1. Key market trends, growth factors and opportunities
6.4.2. Market size and forecast, by region
6.4.3. Market share analysis by country
CHAPTER 7: GENERIC DRUGS MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast By Region
7.2. North America
7.2.1. Key trends and opportunities
7.2.2. Market size and forecast, by Therapeutic Application
7.2.3. Market size and forecast, by Route of Administration
7.2.4. Market size and forecast, by Distribution Channel
7.2.5. Market size and forecast, by country
7.2.5.1. U.S.
7.2.5.1.1. Key market trends, growth factors and opportunities
7.2.5.1.2. Market size and forecast, by Therapeutic Application
7.2.5.1.3. Market size and forecast, by Route of Administration
7.2.5.1.4. Market size and forecast, by Distribution Channel
7.2.5.2. Canada
7.2.5.2.1. Key market trends, growth factors and opportunities
7.2.5.2.2. Market size and forecast, by Therapeutic Application
7.2.5.2.3. Market size and forecast, by Route of Administration
7.2.5.2.4. Market size and forecast, by Distribution Channel
7.2.5.3. Mexico
7.2.5.3.1. Key market trends, growth factors and opportunities
7.2.5.3.2. Market size and forecast, by Therapeutic Application
7.2.5.3.3. Market size and forecast, by Route of Administration
7.2.5.3.4. Market size and forecast, by Distribution Channel
7.3. Europe
7.3.1. Key trends and opportunities
7.3.2. Market size and forecast, by Therapeutic Application
7.3.3. Market size and forecast, by Route of Administration
7.3.4. Market size and forecast, by Distribution Channel
7.3.5. Market size and forecast, by country
7.3.5.1. Germany
7.3.5.1.1. Key market trends, growth factors and opportunities
7.3.5.1.2. Market size and forecast, by Therapeutic Application
7.3.5.1.3. Market size and forecast, by Route of Administration
7.3.5.1.4. Market size and forecast, by Distribution Channel
7.3.5.2. France
7.3.5.2.1. Key market trends, growth factors and opportunities
7.3.5.2.2. Market size and forecast, by Therapeutic Application
7.3.5.2.3. Market size and forecast, by Route of Administration
7.3.5.2.4. Market size and forecast, by Distribution Channel
7.3.5.3. UK
7.3.5.3.1. Key market trends, growth factors and opportunities
7.3.5.3.2. Market size and forecast, by Therapeutic Application
7.3.5.3.3. Market size and forecast, by Route of Administration
7.3.5.3.4. Market size and forecast, by Distribution Channel
7.3.5.4. Italy
7.3.5.4.1. Key market trends, growth factors and opportunities
7.3.5.4.2. Market size and forecast, by Therapeutic Application
7.3.5.4.3. Market size and forecast, by Route of Administration
7.3.5.4.4. Market size and forecast, by Distribution Channel
7.3.5.5. Spain
7.3.5.5.1. Key market trends, growth factors and opportunities
7.3.5.5.2. Market size and forecast, by Therapeutic Application
7.3.5.5.3. Market size and forecast, by Route of Administration
7.3.5.5.4. Market size and forecast, by Distribution Channel
7.3.5.6. Rest of Europe
7.3.5.6.1. Key market trends, growth factors and opportunities
7.3.5.6.2. Market size and forecast, by Therapeutic Application
7.3.5.6.3. Market size and forecast, by Route of Administration
7.3.5.6.4. Market size and forecast, by Distribution Channel
7.4. Asia-Pacific
7.4.1. Key trends and opportunities
7.4.2. Market size and forecast, by Therapeutic Application
7.4.3. Market size and forecast, by Route of Administration
7.4.4. Market size and forecast, by Distribution Channel
7.4.5. Market size and forecast, by country
7.4.5.1. China
7.4.5.1.1. Key market trends, growth factors and opportunities
7.4.5.1.2. Market size and forecast, by Therapeutic Application
7.4.5.1.3. Market size and forecast, by Route of Administration
7.4.5.1.4. Market size and forecast, by Distribution Channel
7.4.5.2. Japan
7.4.5.2.1. Key market trends, growth factors and opportunities
7.4.5.2.2. Market size and forecast, by Therapeutic Application
7.4.5.2.3. Market size and forecast, by Route of Administration
7.4.5.2.4. Market size and forecast, by Distribution Channel
7.4.5.3. India
7.4.5.3.1. Key market trends, growth factors and opportunities
7.4.5.3.2. Market size and forecast, by Therapeutic Application
7.4.5.3.3. Market size and forecast, by Route of Administration
7.4.5.3.4. Market size and forecast, by Distribution Channel
7.4.5.4. Australia
7.4.5.4.1. Key market trends, growth factors and opportunities
7.4.5.4.2. Market size and forecast, by Therapeutic Application
7.4.5.4.3. Market size and forecast, by Route of Administration
7.4.5.4.4. Market size and forecast, by Distribution Channel
7.4.5.5. South Korea
7.4.5.5.1. Key market trends, growth factors and opportunities
7.4.5.5.2. Market size and forecast, by Therapeutic Application
7.4.5.5.3. Market size and forecast, by Route of Administration
7.4.5.5.4. Market size and forecast, by Distribution Channel
7.4.5.6. Rest of Asia-Pacific
7.4.5.6.1. Key market trends, growth factors and opportunities
7.4.5.6.2. Market size and forecast, by Therapeutic Application
7.4.5.6.3. Market size and forecast, by Route of Administration
7.4.5.6.4. Market size and forecast, by Distribution Channel
7.5. LAMEA
7.5.1. Key trends and opportunities
7.5.2. Market size and forecast, by Therapeutic Application
7.5.3. Market size and forecast, by Route of Administration
7.5.4. Market size and forecast, by Distribution Channel
7.5.5. Market size and forecast, by country
7.5.5.1. Brazil
7.5.5.1.1. Key market trends, growth factors and opportunities
7.5.5.1.2. Market size and forecast, by Therapeutic Application
7.5.5.1.3. Market size and forecast, by Route of Administration
7.5.5.1.4. Market size and forecast, by Distribution Channel
7.5.5.2. Saudi Arabia
7.5.5.2.1. Key market trends, growth factors and opportunities
7.5.5.2.2. Market size and forecast, by Therapeutic Application
7.5.5.2.3. Market size and forecast, by Route of Administration
7.5.5.2.4. Market size and forecast, by Distribution Channel
7.5.5.3. South Africa
7.5.5.3.1. Key market trends, growth factors and opportunities
7.5.5.3.2. Market size and forecast, by Therapeutic Application
7.5.5.3.3. Market size and forecast, by Route of Administration
7.5.5.3.4. Market size and forecast, by Distribution Channel
7.5.5.4. Rest of LAMEA
7.5.5.4.1. Key market trends, growth factors and opportunities
7.5.5.4.2. Market size and forecast, by Therapeutic Application
7.5.5.4.3. Market size and forecast, by Route of Administration
7.5.5.4.4. Market size and forecast, by Distribution Channel
CHAPTER 8: COMPETITIVE LANDSCAPE
8.1. Introduction
8.2. Top winning strategies
8.3. Product Mapping of Top 10 Player
8.4. Competitive Dashboard
8.5. Competitive Heatmap
8.6. Top player positioning, 2022
CHAPTER 9: COMPANY PROFILES
9.1. Amneal Pharmaceuticals, Inc.
9.1.1. Company overview
9.1.2. Key Executives
9.1.3. Company snapshot
9.1.4. Operating business segments
9.1.5. Product portfolio
9.1.6. Business performance
9.2. GlaxoSmithKline plc
9.2.1. Company overview
9.2.2. Key Executives
9.2.3. Company snapshot
9.2.4. Operating business segments
9.2.5. Product portfolio
9.2.6. Business performance
9.3. Novartis AG
9.3.1. Company overview
9.3.2. Key Executives
9.3.3. Company snapshot
9.3.4. Operating business segments
9.3.5. Product portfolio
9.3.6. Business performance
9.4. Teva Pharmaceutical Industries Limited
9.4.1. Company overview
9.4.2. Key Executives
9.4.3. Company snapshot
9.4.4. Operating business segments
9.4.5. Product portfolio
9.4.6. Business performance
9.5. Viatris Inc.
9.5.1. Company overview
9.5.2. Key Executives
9.5.3. Company snapshot
9.5.4. Operating business segments
9.5.5. Product portfolio
9.5.6. Business performance
9.5.7. Key strategic moves and developments
9.6. Sun Pharmaceutical Industries Ltd
9.6.1. Company overview
9.6.2. Key Executives
9.6.3. Company snapshot
9.6.4. Operating business segments
9.6.5. Product portfolio
9.6.6. Business performance
9.7. Cipla Ltd
9.7.1. Company overview
9.7.2. Key Executives
9.7.3. Company snapshot
9.7.4. Operating business segments
9.7.5. Product portfolio
9.7.6. Business performance
9.8. Hikma Pharmaceuticals PLC
9.8.1. Company overview
9.8.2. Key Executives
9.8.3. Company snapshot
9.8.4. Operating business segments
9.8.5. Product portfolio
9.8.6. Business performance
9.9. Lupin
9.9.1. Company overview
9.9.2. Key Executives
9.9.3. Company snapshot
9.9.4. Operating business segments
9.9.5. Product portfolio
9.9.6. Business performance
9.9.7. Key strategic moves and developments
9.10. Aurobindo Pharma
9.10.1. Company overview
9.10.2. Key Executives
9.10.3. Company snapshot
9.10.4. Operating business segments
9.10.5. Product portfolio
9.10.6. Business performance
LIST OF TABLES
TABLE 01. GLOBAL GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 02. GENERIC DRUGS MARKET FOR CARDIOVASCULAR, BY REGION, 2022-2032 ($MILLION)
TABLE 03. GENERIC DRUGS MARKET FOR INFECTIOUS DISEASES, BY REGION, 2022-2032 ($MILLION)
TABLE 04. GENERIC DRUGS MARKET FOR CANCER, BY REGION, 2022-2032 ($MILLION)
TABLE 05. GENERIC DRUGS MARKET FOR DIABETES, BY REGION, 2022-2032 ($MILLION)
TABLE 06. GENERIC DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 07. GLOBAL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 08. GENERIC DRUGS MARKET FOR ORAL, BY REGION, 2022-2032 ($MILLION)
TABLE 09. GENERIC DRUGS MARKET FOR INJECTIONS, BY REGION, 2022-2032 ($MILLION)
TABLE 10. GENERIC DRUGS MARKET FOR OTHERS, BY REGION, 2022-2032 ($MILLION)
TABLE 11. GLOBAL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 12. GENERIC DRUGS MARKET FOR HOSPITAL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 13. GENERIC DRUGS MARKET FOR RETAIL PHARMACIES, BY REGION, 2022-2032 ($MILLION)
TABLE 14. GENERIC DRUGS MARKET FOR ONLINE PROVIDERS, BY REGION, 2022-2032 ($MILLION)
TABLE 15. GENERIC DRUGS MARKET, BY REGION, 2022-2032 ($MILLION)
TABLE 16. NORTH AMERICA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 17. NORTH AMERICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 18. NORTH AMERICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 19. NORTH AMERICA GENERIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 20. U.S. GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 21. U.S. GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 22. U.S. GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 23. CANADA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 24. CANADA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 25. CANADA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 26. MEXICO GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 27. MEXICO GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 28. MEXICO GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 29. EUROPE GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 30. EUROPE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 31. EUROPE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 32. EUROPE GENERIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 33. GERMANY GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 34. GERMANY GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 35. GERMANY GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 36. FRANCE GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 37. FRANCE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 38. FRANCE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 39. UK GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 40. UK GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 41. UK GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 42. ITALY GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 43. ITALY GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 44. ITALY GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 45. SPAIN GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 46. SPAIN GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 47. SPAIN GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 48. REST OF EUROPE GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 49. REST OF EUROPE GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 50. REST OF EUROPE GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 51. ASIA-PACIFIC GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 52. ASIA-PACIFIC GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 53. ASIA-PACIFIC GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 54. ASIA-PACIFIC GENERIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 55. CHINA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 56. CHINA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 57. CHINA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 58. JAPAN GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 59. JAPAN GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 60. JAPAN GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 61. INDIA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 62. INDIA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 63. INDIA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 64. AUSTRALIA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 65. AUSTRALIA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 66. AUSTRALIA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 67. SOUTH KOREA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 68. SOUTH KOREA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 69. SOUTH KOREA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 70. REST OF ASIA-PACIFIC GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 71. REST OF ASIA-PACIFIC GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 72. REST OF ASIA-PACIFIC GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 73. LAMEA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 74. LAMEA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 75. LAMEA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 76. LAMEA GENERIC DRUGS MARKET, BY COUNTRY, 2022-2032 ($MILLION)
TABLE 77. BRAZIL GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 78. BRAZIL GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 79. BRAZIL GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 80. SAUDI ARABIA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 81. SAUDI ARABIA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 82. SAUDI ARABIA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 83. SOUTH AFRICA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 84. SOUTH AFRICA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 85. SOUTH AFRICA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 86. REST OF LAMEA GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022-2032 ($MILLION)
TABLE 87. REST OF LAMEA GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022-2032 ($MILLION)
TABLE 88. REST OF LAMEA GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022-2032 ($MILLION)
TABLE 89. AMNEAL PHARMACEUTICALS, INC.: KEY EXECUTIVES
TABLE 90. AMNEAL PHARMACEUTICALS, INC.: COMPANY SNAPSHOT
TABLE 91. AMNEAL PHARMACEUTICALS, INC.: PRODUCT SEGMENTS
TABLE 92. AMNEAL PHARMACEUTICALS, INC.: PRODUCT PORTFOLIO
TABLE 93. GLAXOSMITHKLINE PLC: KEY EXECUTIVES
TABLE 94. GLAXOSMITHKLINE PLC: COMPANY SNAPSHOT
TABLE 95. GLAXOSMITHKLINE PLC: PRODUCT SEGMENTS
TABLE 96. GLAXOSMITHKLINE PLC: PRODUCT PORTFOLIO
TABLE 97. NOVARTIS AG: KEY EXECUTIVES
TABLE 98. NOVARTIS AG: COMPANY SNAPSHOT
TABLE 99. NOVARTIS AG: PRODUCT SEGMENTS
TABLE 100. NOVARTIS AG: PRODUCT PORTFOLIO
TABLE 101. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: KEY EXECUTIVES
TABLE 102. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: COMPANY SNAPSHOT
TABLE 103. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT SEGMENTS
TABLE 104. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: PRODUCT PORTFOLIO
TABLE 105. VIATRIS INC.: KEY EXECUTIVES
TABLE 106. VIATRIS INC.: COMPANY SNAPSHOT
TABLE 107. VIATRIS INC.: PRODUCT SEGMENTS
TABLE 108. VIATRIS INC.: PRODUCT PORTFOLIO
TABLE 109. VIATRIS INC.: KEY STRATERGIES
TABLE 110. SUN PHARMACEUTICAL INDUSTRIES LTD: KEY EXECUTIVES
TABLE 111. SUN PHARMACEUTICAL INDUSTRIES LTD: COMPANY SNAPSHOT
TABLE 112. SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCT SEGMENTS
TABLE 113. SUN PHARMACEUTICAL INDUSTRIES LTD: PRODUCT PORTFOLIO
TABLE 114. CIPLA LTD: KEY EXECUTIVES
TABLE 115. CIPLA LTD: COMPANY SNAPSHOT
TABLE 116. CIPLA LTD: PRODUCT SEGMENTS
TABLE 117. CIPLA LTD: PRODUCT PORTFOLIO
TABLE 118. HIKMA PHARMACEUTICALS PLC: KEY EXECUTIVES
TABLE 119. HIKMA PHARMACEUTICALS PLC: COMPANY SNAPSHOT
TABLE 120. HIKMA PHARMACEUTICALS PLC: PRODUCT SEGMENTS
TABLE 121. HIKMA PHARMACEUTICALS PLC: PRODUCT PORTFOLIO
TABLE 122. LUPIN: KEY EXECUTIVES
TABLE 123. LUPIN: COMPANY SNAPSHOT
TABLE 124. LUPIN: PRODUCT SEGMENTS
TABLE 125. LUPIN: PRODUCT PORTFOLIO
TABLE 126. LUPIN: KEY STRATERGIES
TABLE 127. AUROBINDO PHARMA: KEY EXECUTIVES
TABLE 128. AUROBINDO PHARMA: COMPANY SNAPSHOT
TABLE 129. AUROBINDO PHARMA: PRODUCT SEGMENTS
TABLE 130. AUROBINDO PHARMA: PRODUCT PORTFOLIO
LIST OF FIGURES
FIGURE 01. GENERIC DRUGS MARKET, 2022-2032
FIGURE 02. SEGMENTATION OF GENERIC DRUGS MARKET, 2022-2032
FIGURE 03. TOP INVESTMENT POCKETS IN GENERIC DRUGS MARKET (2023-2032)
FIGURE 04. MODERATE BARGAINING POWER OF SUPPLIERS
FIGURE 05. MODERATE THREAT OF NEW ENTRANTS
FIGURE 06. MODERATE THREAT OF SUBSTITUTES
FIGURE 07. MODERATE INTENSITY OF RIVALRY
FIGURE 08. MODERATE BARGAINING POWER OF BUYERS
FIGURE 09. DRIVERS, RESTRAINTS AND OPPORTUNITIES: GLOBALGENERIC DRUGS MARKET
FIGURE 09. GENERIC DRUGS MARKET, BY THERAPEUTIC APPLICATION, 2022(%)
FIGURE 10. COMPARATIVE SHARE ANALYSIS OF GENERIC DRUGS MARKET FOR CARDIOVASCULAR, BY COUNTRY 2022 AND 2032(%)
FIGURE 11. COMPARATIVE SHARE ANALYSIS OF GENERIC DRUGS MARKET FOR INFECTIOUS DISEASES, BY COUNTRY 2022 AND 2032(%)
FIGURE 12. COMPARATIVE SHARE ANALYSIS OF GENERIC DRUGS MARKET FOR CANCER, BY COUNTRY 2022 AND 2032(%)
FIGURE 13. COMPARATIVE SHARE ANALYSIS OF GENERIC DRUGS MARKET FOR DIABETES, BY COUNTRY 2022 AND 2032(%)
FIGURE 14. COMPARATIVE SHARE ANALYSIS OF GENERIC DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 15. GENERIC DRUGS MARKET, BY ROUTE OF ADMINISTRATION, 2022(%)
FIGURE 16. COMPARATIVE SHARE ANALYSIS OF GENERIC DRUGS MARKET FOR ORAL, BY COUNTRY 2022 AND 2032(%)
FIGURE 17. COMPARATIVE SHARE ANALYSIS OF GENERIC DRUGS MARKET FOR INJECTIONS, BY COUNTRY 2022 AND 2032(%)
FIGURE 18. COMPARATIVE SHARE ANALYSIS OF GENERIC DRUGS MARKET FOR OTHERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 19. GENERIC DRUGS MARKET, BY DISTRIBUTION CHANNEL, 2022(%)
FIGURE 20. COMPARATIVE SHARE ANALYSIS OF GENERIC DRUGS MARKET FOR HOSPITAL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 21. COMPARATIVE SHARE ANALYSIS OF GENERIC DRUGS MARKET FOR RETAIL PHARMACIES, BY COUNTRY 2022 AND 2032(%)
FIGURE 22. COMPARATIVE SHARE ANALYSIS OF GENERIC DRUGS MARKET FOR ONLINE PROVIDERS, BY COUNTRY 2022 AND 2032(%)
FIGURE 23. GENERIC DRUGS MARKET BY REGION, 2022
FIGURE 24. U.S. GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 25. CANADA GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 26. MEXICO GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 27. GERMANY GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 28. FRANCE GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 29. UK GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 30. ITALY GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 31. SPAIN GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 32. REST OF EUROPE GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 33. CHINA GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 34. JAPAN GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 35. INDIA GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 36. AUSTRALIA GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 37. SOUTH KOREA GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 38. REST OF ASIA-PACIFIC GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 39. BRAZIL GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 40. SAUDI ARABIA GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 41. SOUTH AFRICA GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 42. REST OF LAMEA GENERIC DRUGS MARKET, 2022-2032 ($MILLION)
FIGURE 43. TOP WINNING STRATEGIES, BY YEAR
FIGURE 44. TOP WINNING STRATEGIES, BY DEVELOPMENT
FIGURE 45. TOP WINNING STRATEGIES, BY COMPANY
FIGURE 46. PRODUCT MAPPING OF TOP 10 PLAYERS
FIGURE 47. COMPETITIVE DASHBOARD
FIGURE 48. COMPETITIVE HEATMAP: GENERIC DRUGS MARKET
FIGURE 49. TOP PLAYER POSITIONING, 2022
FIGURE 50. AMNEAL PHARMACEUTICALS, INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 51. AMNEAL PHARMACEUTICALS, INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 52. GLAXOSMITHKLINE PLC: NET SALES, 2020-2022 ($MILLION)
FIGURE 53. GLAXOSMITHKLINE PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 54. GLAXOSMITHKLINE PLC: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 55. NOVARTIS AG: NET SALES, 2020-2022 ($MILLION)
FIGURE 56. NOVARTIS AG: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 57. NOVARTIS AG: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 58. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 59. TEVA PHARMACEUTICAL INDUSTRIES LIMITED: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 60. VIATRIS INC.: NET SALES, 2020-2022 ($MILLION)
FIGURE 61. VIATRIS INC.: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 62. SUN PHARMACEUTICAL INDUSTRIES LTD: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 63. SUN PHARMACEUTICAL INDUSTRIES LTD: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 64. CIPLA LTD: SALES REVENUE, 2020-2022 ($MILLION)
FIGURE 65. CIPLA LTD: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 66. CIPLA LTD: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 67. HIKMA PHARMACEUTICALS PLC: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 68. HIKMA PHARMACEUTICALS PLC: REVENUE SHARE BY SEGMENT, 2022 (%)
FIGURE 69. HIKMA PHARMACEUTICALS PLC: REVENUE SHARE BY REGION, 2021 (%)
FIGURE 70. LUPIN: NET SALES, 2020-2022 ($MILLION)
FIGURE 71. LUPIN: REVENUE SHARE BY REGION, 2022 (%)
FIGURE 72. AUROBINDO PHARMA: NET REVENUE, 2020-2022 ($MILLION)
FIGURE 73. AUROBINDO PHARMA: REVENUE SHARE BY REGION, 2021 (%)
- Not Sure / Need Reassuring
- Confirm Content
-
Content is provided by our partners and every effort is made to make Market Report details as clear as possible. If you are not sure the exact content you require is included in this study you can Contact us to double check. To do this you can:
Use the ‘? ASK A QUESTION’ below the license / prices and to the right of this box. This will come directly to our team who will work on dealing with your request as soon as possible.
Write to directly on support@scotts-international.com with details. Please include as much information as possible including the name of report or link so our staff will be able to work on you request.
Telephone us directly on 0048 603 394 346 and an experienced member of team will be on hand to answer.
-
- Sample Pages
-
With the vast majority of our partners we can obtain Sample Pages to support your decision. This is something we can arrange without revealing your personal details.
It is important to note that we will not be able to provide you the exact data or statistics such as Market Size and Forecasts. Sample pages usually confirm the layout or the Categories included in Charts and Graphs, excluding specific data.
To ask for Sample Pages by contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Check for Alternatives
-
Whilst we try to make our online platform as easy to use as possible there is always the possibility that a better alternative has not been found in your search.
To avoid this possibility Contact us through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346 and a Senior Team Member can review your requirements and send a list of possibilities with opinions and recommendations.
-
- Confirm Content
- Prices / Formats / Delivery
- Prices
-
All prices are set by our partners and should be exactly the same as those listed on their own websites. We work on a Revenue share basis ensuring that you never pay more than what is offered elsewhere.
Should you find the price cheaper on another platform we recommend you to Contact us as we should be able to match this price. You can Contact us though through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Discounts
-
As we work in close partnership with our Partners from time to time we can secure discounts and assist with negotiations, this is part of our personalised service to you.
Discounts can sometimes be arranged for speedily placed orders; multiple report purchases or Higher License purchases.
To check if a Discount is possible please Contact our experienced team through ‘? ASK A QUESTION’, support@scotts-international.com, or by telephoning 0048 603 394 346.
-
- Available Currencies
-
Most Market Reports on our platform are listed in USD or EURO based on the wishes of our Partners. To avoid currency fluctuations and potential price differentiations we do not offer the possibility to change the currency online.
Should you wish to pay in a different currency to that advertised online we do accept payments in USD, EURO, GBP and PLN. The price will be calculated based on the relevant exchange rate taken from our National Bank.
To pay in a different above currency to that advertised online please Contact our team and a quotation will be sent within a couple of hours with payment details.
-
- Licenses
-
License options vary from Partner to Partner as is usually based on the number of Users that will benefitting from the report. It is very important that License ordered is not breached as this could have potential negative consequences for you individually or your employer.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Global Site License
-
The Global Site License is the most comprehensive license available. By selecting this license, the Market Report can be shared with other ‘Allowed Users’ and any other member of staff from the same organisation regardless of geographic location.
It is important to note that this may exclude Parent Companies or Subsidiaries.
If you have questions or need confirmation about the specific license we recommend you to Contact us and a detailed explanation will be provided.
-
- Formats
-
The most common format is PDF, however in certain circumstances data may be present in Excel format or Online, especially in the case of Database or Directories. In addition, for certain higher license options a CD may also be provided.
If you have questions or need clarification about the specific formats we recommend you to Contact us and a detailed explanation will be provided.
-
- Delivery
-
Delivery is fulfilled by our partners directly. Once an order has been placed we inform the partner by sharing the delivery email details given in the order process.
Delivery is usually made within 24 hours of an order being placed, however it may take longer should your order be placed prior to the weekend or if otherwise specified on the Market Report details page. Additionally, if details have been not fully completed in the Order process a delay in delivery is possible.
If a delay in delivery is expected you will be informed about it immediately.
-
- Shipping Charges
-
As most Market Reports are delivered in PDF format we almost never have to add additional Shipping Charges. If, however you are ordering a Higher License service or a specific delivery format (e.g. CD version) charges may apply.
If you are concerned about additional Shipping Charges we recommend you to Contact us to double check.
-
- Prices
- Ordering
- By Credit Card
-
We work in Partnership with PayU to ensure payments are made securely in a fast and effortless way. PayU is the e-payments division of Naspers.
Naspers operates in over 133 International Markets and ranks 3rd Globally in terms of the number of e-commerce customers served.
For more information on PayU please visit: https://www.payu.pl/en/about-us
-
- By Money Transfer
-
If you require an invoice prior to payment, this is possible. To ensure a speedy delivery of the Market Report we require all relevant company details and you agree to maximum payment terms of 30 days from receipt of order.
With our regular clients deliver of the Market Report can be made prior to receiving payment, however in some circumstances we may ask for payment to be received before arranging for the Market Report to be delivered.
-
- By Credit Card
- Security
- Website security
-
We have specifically partnered with leading International companies to protect your privacy by using different technologies and processes to ensure security.
Everything submitted to Scotts International is encrypted via SSL (Secure Socket Layer) and all personal information provided to Scotts International is stored on computer systems with limited access in controlled environments.
-
- Credit Card Security
-
We partner with PayU (https://www.payu.pl/en/about-us) to ensure all credit card payments are made securely in a fast and effortless way.
PayU offers 250+ various payment channels and eWallet services across 4 continents allowing buyers to pay electronically, whether on a computer or a mobile device.
-
- Website security